Summary
Cardiovascular disease (CVD), more specifically, vulnerable plaque rupture, remains the major cause of death for people at middle age. The CVENT consortium will revolutionize screening, diagnosis and monitoring of CVD by means of a compact photoacoustic imaging (PAI) system for vulnerable plaque imaging.
In the carotid arteries feeding the brain, vulnerable plaque rupture initiates cerebrovascular ischemic attacks. The state-of-the-art decision-making approach for a high-risk surgical intervention to avoid plaque rupture is based on stenosis severity alone, measured with ultrasound (US) imaging. However, this does not distinguish between vulnerable (rupture-prone) and stable (harmless) plaques, leading to severe overtreatment. Consequently, there is a worldwide unmet and urgent clinical need for functional information to enable in-depth diagnosis of carotid plaque vulnerability, avoiding cardiovascular events (CVENT) and reducing overtreatment risk.
The objective of the CVENT consortium is the development of a portable multimodal and multiwavelength PAI system with a 3 cm imaging depth, for diagnosis and monitoring of carotid plaque vulnerability. The combination of high optical contrast of PAI and the high resolution of US will be used to identify plaque vulnerability markers, typically lipid pools and intra-plaque haemorrhage. Improved diagnosis of carotid plaque vulnerability will lead to a significant reduction in CVD-related disability and mortality. Simultaneously, by stratifying patients into high and low risk groups, overtreatment is reduced, leading to better allocation of healthcare funds.
The CVENT consortium unites leading research groups, clinicians, industrial partners, and their expertise on R&D and a focus on exploitation, creating a breakthrough in carotid plaque vulnerability diagnosis. CVENT will bring together leading experts in the field of CVD, functional US imaging and PAI, introducing clinically applied PAI into the vascular medical arena.
In the carotid arteries feeding the brain, vulnerable plaque rupture initiates cerebrovascular ischemic attacks. The state-of-the-art decision-making approach for a high-risk surgical intervention to avoid plaque rupture is based on stenosis severity alone, measured with ultrasound (US) imaging. However, this does not distinguish between vulnerable (rupture-prone) and stable (harmless) plaques, leading to severe overtreatment. Consequently, there is a worldwide unmet and urgent clinical need for functional information to enable in-depth diagnosis of carotid plaque vulnerability, avoiding cardiovascular events (CVENT) and reducing overtreatment risk.
The objective of the CVENT consortium is the development of a portable multimodal and multiwavelength PAI system with a 3 cm imaging depth, for diagnosis and monitoring of carotid plaque vulnerability. The combination of high optical contrast of PAI and the high resolution of US will be used to identify plaque vulnerability markers, typically lipid pools and intra-plaque haemorrhage. Improved diagnosis of carotid plaque vulnerability will lead to a significant reduction in CVD-related disability and mortality. Simultaneously, by stratifying patients into high and low risk groups, overtreatment is reduced, leading to better allocation of healthcare funds.
The CVENT consortium unites leading research groups, clinicians, industrial partners, and their expertise on R&D and a focus on exploitation, creating a breakthrough in carotid plaque vulnerability diagnosis. CVENT will bring together leading experts in the field of CVD, functional US imaging and PAI, introducing clinically applied PAI into the vascular medical arena.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/731771 |
| Start date: | 01-11-2016 |
| End date: | 30-04-2020 |
| Total budget - Public funding: | 4 697 377,50 Euro - 4 260 790,00 Euro |
Cordis data
Original description
Cardiovascular disease (CVD), more specifically, vulnerable plaque rupture, remains the major cause of death for people at middle age. The CVENT consortium will revolutionize screening, diagnosis and monitoring of CVD by means of a compact photoacoustic imaging (PAI) system for vulnerable plaque imaging.In the carotid arteries feeding the brain, vulnerable plaque rupture initiates cerebrovascular ischemic attacks. The state-of-the-art decision-making approach for a high-risk surgical intervention to avoid plaque rupture is based on stenosis severity alone, measured with ultrasound (US) imaging. However, this does not distinguish between vulnerable (rupture-prone) and stable (harmless) plaques, leading to severe overtreatment. Consequently, there is a worldwide unmet and urgent clinical need for functional information to enable in-depth diagnosis of carotid plaque vulnerability, avoiding cardiovascular events (CVENT) and reducing overtreatment risk.
The objective of the CVENT consortium is the development of a portable multimodal and multiwavelength PAI system with a 3 cm imaging depth, for diagnosis and monitoring of carotid plaque vulnerability. The combination of high optical contrast of PAI and the high resolution of US will be used to identify plaque vulnerability markers, typically lipid pools and intra-plaque haemorrhage. Improved diagnosis of carotid plaque vulnerability will lead to a significant reduction in CVD-related disability and mortality. Simultaneously, by stratifying patients into high and low risk groups, overtreatment is reduced, leading to better allocation of healthcare funds.
The CVENT consortium unites leading research groups, clinicians, industrial partners, and their expertise on R&D and a focus on exploitation, creating a breakthrough in carotid plaque vulnerability diagnosis. CVENT will bring together leading experts in the field of CVD, functional US imaging and PAI, introducing clinically applied PAI into the vascular medical arena.
Status
CLOSEDCall topic
ICT-29-2016Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Search
Organisations
-
| ESAOTE EUROPE B.V. (Coördinator)
-
| BRIGHTLOOP SAS
-
| Eindhoven University of Technology
-
| GROUPE HOSPITALIER UNIVERSITAIRE PARIS PSYCHIATRIE ET NEUROSCIENCES
-
| LUMIBIRD (LUMIBIRD)
-
| RUHR-UNIVERSITAET BOCHUM
-
| SILIOS TECHNOLOGIES SA (SILIOS)
-
| TP21 GMBH
-
| UNIVERSITAET BERN
-
| UNIVERSITE PARIS CITE
-
| UNIVERSITEIT TWENTE